Exact Sciences background and strategy, shares on NASDAQ in a diagnostics peer view

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 10:50.

Exact Sciences (US30063P1057) is a US diagnostics company whose shares trade on NASDAQ, positioning the stock directly in the US growth segment for medical technology and life sciences. The Sunday view highlights its long-term cancer screening strategy and competitive backdrop in molecular diagnostics.

Where Exact Sciences came from

Exact Sciences was founded in 1995 in Madison, Wisconsin, and over roughly three decades has focused on improving early detection of cancer through non-invasive diagnostic tests, with a particular emphasis on colorectal cancer screening.

Colorectal cancer screening became the company’s anchor starting point, supported by US regulatory and guideline acceptance for stool-based DNA tests, which differentiated Exact Sciences from conventional colonoscopy-focused approaches.

The move into cancer screening leadership

The company’s best-known product, the Cologuard stool DNA test, gained US Food and Drug Administration (FDA) approval for colorectal cancer screening and is covered by the Centers for Medicare & Medicaid Services (CMS), which underpins broad US adoption and recurring test volumes.

Cologuard targets average-risk adults aged 45 and above for colorectal cancer screening, providing a non-invasive alternative to colonoscopy that can be conducted at home, which supports patient adherence and a wider screening base in the US population.

Why US guidelines mattered

US screening guidelines from organizations such as the US Preventive Services Task Force recognize stool-based DNA testing as a valid option for colorectal cancer screening, which supports medical acceptance of Exact Sciences’ core test category and helps physicians integrate the offering.

This guideline support has contributed to growing screening rates in the US and provides a structured framework for payers to reimburse stool-based DNA tests, reinforcing the company’s long-term revenue visibility in colorectal screening.

Expansion beyond colorectal cancer

Beyond colorectal cancer, Exact Sciences has built a broader oncology diagnostics portfolio through liquid biopsy and tissue-based tests for breast, prostate and other cancers, aiming to cover the full continuum from screening to diagnosis and treatment monitoring.

This portfolio expansion reflects a strategic push to be present at multiple stages of the cancer care pathway, which diversifies revenue sources and reduces dependence on any single test within the oncology landscape.

Acquisitions as a strategy tool

Exact Sciences has historically used acquisitions to deepen its presence in genomics and oncology diagnostics, including deals for companies with expertise in liquid biopsy, molecular profiling and hereditary cancer testing.

Through these transactions, Exact Sciences has gained additional platforms, intellectual property and commercial capabilities that complement its organic development activities, a pattern that has been consistent in US diagnostics consolidation.

Position on NASDAQ among diagnostics peers

Exact Sciences shares are listed on NASDAQ alongside peers such as Illumina, Guardant Health and Natera, placing the company within a cohort of US-listed diagnostics and genomics firms that have focused on precision medicine and advanced cancer detection technologies.

This NASDAQ peer group is characterized by high research and development spending and a focus on biomarker discovery and sequencing; Exact Sciences participates in this landscape with its oncology-focused testing portfolio rather than pure sequencing instrumentation like Illumina.

Cancer screening economics and recurring revenue

Cancer screening creates the potential for recurring revenue streams because eligible patients undergo tests at defined intervals, such as colorectal screening every several years, which means tests like Cologuard can generate repeat demand in each screening cycle.

Reimbursement agreements with public and private payers give Exact Sciences visibility on pricing and coverage, forming a key component of its long-term business model and supporting planning for capacity and test throughput in its laboratories.

Laboratory and processing capacity

Exact Sciences operates dedicated laboratory facilities to process its stool-based and blood-based tests, where samples are analyzed using proprietary workflows and biomarker panels tailored to each cancer type and test format.

Scaling laboratory capacity efficiently is important because test volumes can fluctuate with screening campaigns, guideline changes and physician adoption trends, requiring flexible infrastructure to manage throughput without compromising turnaround times.

Technology base in molecular diagnostics

The company’s tests rely on molecular diagnostics techniques such as DNA mutation analysis, methylation patterns and other genomic markers associated with cancer presence, which are detected in stool or blood samples; this approach is aligned with broader precision medicine trends.

Such molecular methods aim to identify cancer-related signatures that can be present even when tumors are small, supporting early detection and potentially improving outcomes if follow-up diagnostic procedures and treatments occur promptly after a positive screening result.

Regulatory framework and compliance

Exact Sciences operates within the US regulatory framework for in vitro diagnostics, including FDA approvals for specific test indications and Clinical Laboratory Improvement Amendments (CLIA) requirements for its laboratory operations.

Maintaining compliance with these rules is essential for the company to sell its tests across US states and to contract with hospitals, clinics and health systems, forming a baseline for its long-term operating model.

Commercial partnerships and physician reach

The company markets its tests to primary care physicians, gastroenterologists and other specialists who play a role in recommending screening; its salesforce and educational activities are key tools to increase physician awareness and comfort with stool-based DNA testing.

Physician adoption influences how quickly new screening options become part of routine practice, and continued communication about guideline updates and test performance helps Exact Sciences maintain its position in the colorectal screening dialogue.

Role of health systems and payers

US health systems and payers use screening programs to manage long-term cancer risk in covered populations; by offering reimbursed tests like Cologuard, they can encourage non-invasive screening and potentially reduce late-stage cancer treatment costs over time.

Exact Sciences therefore operates at the intersection of clinical guidelines, payer policy and patient behavior, with each of these factors influencing the sustainable demand for its cancer screening tests.

Competitive landscape in oncology diagnostics

In oncology diagnostics, Exact Sciences faces competition from companies offering colonoscopy, fecal immunochemical tests (FIT), liquid biopsy solutions and multi-cancer detection tests, making performance, convenience and cost important comparative dimensions.

Within this landscape, Exact Sciences differentiates its colorectal screening product through a combination of sensitivity, ease of at-home sampling and guideline support, while its broader oncology portfolio provides additional tools across various cancer indications.

Research and development commitment

Like many NASDAQ-listed diagnostics companies, Exact Sciences invests in research and development to refine its biomarkers, improve test accuracy and expand into new cancer types and indications, which can be resource-intensive but central to long-term competitiveness.

R&D activities may include clinical studies, validation work in diverse patient populations and collaborations with academic centers, contributing to data that can support regulatory submissions or guideline inclusion for new test applications.

Long-term strategy in early detection

Strategically, Exact Sciences emphasizes the importance of early cancer detection as a means to improve outcomes and reduce mortality, aligning its mission with public health goals that favor regular screening and proactive healthcare engagement.

This focus on early detection shapes its product roadmap, marketing messaging and partnerships, positioning the company as a proponent of preventive oncology rather than solely late-stage disease management.

Data generation and evidence base

Large-scale screening programs and ongoing test usage generate data on test performance, patient adherence and downstream diagnostic procedures, which can be analyzed to refine protocols and support further publications related to Exact Sciences’ products.

A strong evidence base in peer-reviewed literature strengthens the company’s case with clinicians and guideline committees, making data generation a structural element of its long-term business and scientific strategy.

Digital tools and patient engagement

Exact Sciences provides logistical and support materials to help patients complete at-home stool tests properly, which can include instructions and reminder mechanisms that form part of its patient engagement approach.

Effective patient engagement is important because incomplete or improperly collected samples can reduce the efficiency of screening campaigns and laboratory throughput, affecting both clinical and operational outcomes for the company.

Integration with primary care workflows

For primary care physicians, incorporating stool-based DNA testing into workflows involves identifying eligible patients, ordering tests, and managing follow-up for positive results, which requires coordination across staff, patients and specialists.

Exact Sciences supports such integration through educational efforts and practice-facing tools, with the aim of making colorectal screening recommendations more straightforward during routine consultations.

Cologuard as a representative product

Cologuard is ordered by physicians, shipped to patients’ homes for stool sample collection, and then returned to Exact Sciences’ labs where DNA markers associated with colorectal cancer are analyzed, with results reported back to the ordering physician.

This workflow illustrates the company’s at-home testing model, combining logistics, laboratory processing and clinical reporting under a single brand and operational umbrella within the US healthcare system.

Comparisons with colonoscopy and FIT

Traditional colonoscopy remains a key screening method, offering direct visualization and polyp removal, whereas stool tests such as Cologuard and FIT provide non-invasive options that can be deployed more broadly, especially for patients reluctant to undergo invasive procedures.

Exact Sciences positions Cologuard within this mix as a tool that can increase screening rates in populations where colonoscopy uptake is limited, potentially identifying individuals who should be referred for follow-up colonoscopy after a positive stool test.

Role of multi-cancer early detection trends

Multi-cancer early detection tests, often based on blood samples, represent a growing segment in oncology diagnostics; while Exact Sciences’ core franchise is colorectal screening, its broader test portfolio and genomics capabilities place it within the same conversation about early detection strategies.

The evolution of multi-cancer detection technologies could influence how colorectal-specific tests are used in combination with broader panels, and companies like Exact Sciences monitor these trends closely for potential complementary offerings.

US demographics and screening demand

US demographic trends, including an aging population and rising awareness of cancer prevention, support demand for screening tools across various cancers, creating a long-term tailwind for companies specializing in diagnostics.

Exact Sciences benefits from these trends in colorectal screening and broader oncology testing, although it must also navigate healthcare cost pressures and payer scrutiny on test value and clinical utility.

Exact Sciences in a diagnostics ecosystem

Within the wider diagnostics ecosystem, Exact Sciences operates alongside imaging, pathology and genomic sequencing providers, with each modality contributing different types of information to cancer diagnosis and management.

Coordination between these modalities can influence how often stool-based and blood-based tests are ordered and how their results are interpreted in the context of other findings, which has implications for Exact Sciences’ role in multi-disciplinary cancer care.

Investor interest and NASDAQ listing

As a NASDAQ-listed company, Exact Sciences attracts attention from US and international investors interested in healthcare innovation, precision medicine and preventive care, particularly those focusing on growth names in the diagnostics and genomics segments.

The NASDAQ venue offers visibility among technology and healthcare issuers and supports liquidity for Exact Sciences shares, forming part of the company’s capital markets presence.

Long-term opportunities and challenges

Key opportunities for Exact Sciences include expanding screening uptake, launching new tests for additional cancer types, and strengthening partnerships with healthcare systems to embed its offerings more deeply in preventive care programs.

At the same time, the company faces challenges related to competition, cost pressures and the need to continually demonstrate clinical value and cost-effectiveness, which shape its long-term strategic decisions in product development and commercialization.

The product behind the stock

At the product level, Cologuard exemplifies Exact Sciences’ approach to non-invasive colorectal cancer screening: patients collect a stool sample at home, which is analyzed for DNA markers associated with cancer and advanced adenomas, providing physicians with actionable screening data independent of colonoscopy scheduling.

Where the shares trade today

The Exact Sciences shares (US30063P1057) trade on NASDAQ in US dollars; a precise intraday price and timestamp for the current session are determined by live NASDAQ trading data, which investors typically access through exchange or broker platforms.

This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data and facts were compiled with care from publicly available sources but cannot be guaranteed for completeness or accuracy. Investors should conduct their own research or consult a professional advisor before making investment decisions.

en | US30063P1057 | EXACT SCIENCES | boerse | 69645402 | bgmi